CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells

Oncogene

Volumn 33, Issue 50, 2014, Pages 5675-5687

  Delehouze C ^a   Godl, K ^b   Loaec N ^a,c   Bruyere C ^a   Desban, N ^c   Oumata, N ^a   Galons, H ^d   Roumeliotis, T I ^e   Giannopoulou, E G ^f   Grenet, J ^g   Twitchell, D ^g   Lahti, J ^g   Mouchet, N ^h   Galibert, M D ^h   Garbis, S D ^e   Meijer, L ^a,c  

^a Centre de Perharidy   (France)

^b Evotec München GmbH   (Germany)

^c Protein Phosphorylation and Human Disease Group   (France)

^d INSERM   (France)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h UNIVERSITÉ DE RENNES 1   (France)

Author keywords

casein kinase 1; CR8; cyclin dependent kinase; MYCN; neuroblastoma; roscovitine

Indexed keywords

CR8 COMPOUND; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; ROSCOVITINE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; NEUROBLASTOMA; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEIN KINASE INHIBITORS; PURINES; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889033432     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.513     Document Type: Article

References (92)

1. Weinmann H, Metternich R. Drug discovery process for kinase inhibitors. ChemBioChem 2005; 6: 455-459.
2. Eglen RM, Reisine T. The current status of drug discovery against the human kinome. Assay. Drug Dev Technol 2009; 7: 22-43.
3. Eglen R, Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol Ther 2011; 130: 144-156.
4. Via MC. Kinase-targeted therapeutics: development pipelines, challenges, and opportunities. Cambridge Healthtech Institute, Needham, MA, USA, 2011, pp 124.
5. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008; 15: 422-432.
6. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-336.
7. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
8. Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008; 7: 391-397.
9. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371: 199-204.
10. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
11. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G et al. Cyclindependent kinases: a family portrait. Nat Cell Biol 2009; 11: 1275-1276.
12. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23: 417-425.
13. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 29: 16-21.
14. Galons H, Oumata N, Gloulou O, Meijer L. Cyclin-dependent kinase inhibitors closer to market launch? Expert Opin Ther Pat. 2013; 23: 945-963.
15. Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert. Opin Ther Targets 2010; 14: 1199-1212.
16. Cirillo D, Pentimalli F, Giordano A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr Med Chem 2011; 18: 2854-2866.
17. Wesierska-Gadek J, Kramer MP. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications. Expert Opin Investig Drugs 2011; 20: 1611-1628.
18. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011; 137: 1409-1418.
19. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003; 36: 417-425.
20. Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008; 27: 5797-5807.
21. Oumata N, Ferandin Y, Meijer L, Galons H. Practical synthesis of roscovitine and CR8. Organic Process Res Dev 2009; 13: 641-644.
22. Bettayeb K, Baunbæk D, Delehouzé C, Loaëc N, Hole A, Baumli S et al. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cell lines. Genes & Cancer 2010; 1: 369-380.
23. Bettayeb K, Sallam HH, Ferandin Y, Popowycz F, Fournet G, Hassan M et al. N-&-N, a new class of cell death-inducing, kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther 2008; 7: 2713-2724.
24. Popowycz F, Fournet G, Schneider C, Bettayeb K, Ferandin Y, Lamigeon C et al. Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent CDK inhibitor (R)-roscovitine analogue. J Med Chem 2009; 52: 655-663.
25. Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard M-L et al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases (CDKs) and casein kinase 1 (CK1). J Med Chem 2008; 51: 5229-5242.
26. Trova MP, Barnes KD, Barford C, Benanti T, Bielaska M, Burry L et al. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I. Bioorg Med Chem Lett 2009; 19: 6608-6612.
27. Trova MP, Barnes KD, Alicea L, Benanti T, Bielaska M, Bilotta J et al. Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II. Bioorg Med Chem Lett 2009; 19: 6613-6617.
28. Jorda R, Paruch K, Krystof V. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres. Curr Pharm Des 2012; 18: 2974-2980.
29. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclindependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527-536.
30. Aldoss IT, Tashi T, Ganti AK. Seliciclib in malignancies. Expert Opin Investig Drugs 2009; 18: 1957-1965.
31. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96: 29-37.
32. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D et al. Pharmacodynamic effects of seliciclib an orally administered cell cycle modulator in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009; 15: 1435-1442.
33. Hui AB, Yue S, Shi W, Alajez NM, Ito E, Green SR et al. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 2009; 15: 3716-3724.
34. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280: 31208-31219.
35. Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005; 280: 31220-31229.
36. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 2005; 9: 327-338.
37. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007; 13: 820-827.
38. Hydbring P, Bahram F, Su Y, Tronnersjö S, Högstrand K, von der Lehr N et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci USA 2009; 107: 58-63.
39. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA 2009; 106: 12968-12973.
40. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67-78.
41. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010; 12: 54-59.
42. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011; 71: 925-936.
43. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012; 209: 679-696.
44. Chen Y, Tsai YH, Tseng SH. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Surgery 2013; 153: 4-16.
45. Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E et al. CDKmediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med 2013; 5: 999-1018.
46. Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A. Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 2009; 9: 176-188.
47. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249-1255.
48. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010; 107: 163-224.
49. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012; 109: 9545-9950.
50. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, Seliciclib). In: Smith P.J, Yue E (eds) Monographs on Enzyme Inhibitors. CDK Inhibitors and their Potential as Anti-tumor Agents. Vol 2, chapter 9. CRC Press, Taylor & Francis: Boca Raton, Fl, 2006, pp 187-226.
51. Becker F, Murthi K, Smith C, Come J, Costa-Roldan N, Kaufmann C et al. A threehybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem Biol 2004; 11: 211-223.
52. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem & Biol 2000; 7: 411-422.
53. Knockaert M, Viking K, Schmitt S, Leost M, Mottram J, Kunick C et al. Intracellular targets of paullones: identification by affinity chromatography using immobilized inhibitor. J Biol Chem 2002; 277: 25493-25501.
54. Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclindependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997; 243: 518-526.
55. Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (&) and the concentration of inhibitor which causes 50 percent inhibition (Iso) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
56. Lovén J, Orlando DA, Sigova AA, Lin CY, Rahl PB, Burge CB, Levens DL, Lee TI, Young RA. Revisiting global gene expression analysis. Cell 2012; 151: 476-482.
57. Gray N, Wodicka L, Thunnissen AM, Norman T, Kwon S, Espinoza FH et al. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 1998; 281: 533-538.
58. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344-2353.
59. Squires MS, Cooke L, Lock V, Qi W, Lewis EJ, Thompson NT et al. AT7519, a cyclindependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 2010; 9: 920-928.
60. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA et al. N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5- (1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004; 47: 1719-1728.
61. Wang LM, Ren DM. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 2010; 10: 1058-1070.
62. Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. Modulation of alternative pre-RNA splicing. J Med Chem 2011; 54: 4172-4186.
63. Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E et al. Selectivity, cocrystal structures and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 2012; 55: 9312-9330.
64. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004; 279: 24246-24254.
65. Behrend L, Milne DM, Stoter M, Deppert W, Campbell LE, Meek DW et al. IC261 a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene 2000; 19: 5303-5313.
66. Rena G, Bain J, Elliott M, Cohen P. D4476 a cell-permeant inhibitor of CK1 suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 2004; 5: 60-65.
67. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
68. Tanramluk D, Schreyer A, Pitt WR, Blundell TL. On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem Biol Drug Des 2009; 74: 16-24.
69. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-6145.
70. Cheng SW, Kuzyk MA, Moradian A, Ichu TA, Chang VC, Tien JF et al. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol Cell Biol 2012; 32: 4691-4704.
71. Dai Q, Lei T, Zhao C, Zhong J, Tang YZ, Chen B et al. Cyclin K-containing kinase complexes maintain self-renewal in murine embryonic stem cells. J Biol Chem 2012; 287: 25344-25352.
72. Blazek D. The cyclin K/Cdk12 complex: an emerging new player in the maintenance of genome stability. Cell Cycle 2012; 11: 1049-1050.
73. Kohoutek J, Blazek D. Cyclin K goes with Cdk12 and Cdk13. Cell Div 2012; 7: 12.
74. Blazek D, Kohoutek J, Bartholomeeusen K, Johansen E, Hulinkova P, Luo Z et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011; 25: 2158-2172.
75. Krystof V, Baumli S, Fürst R. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. Curr Pharm Des 2012; 18: 2883-2890.
76. Larochelle S, Amat R, Glover-Cutter K, Sansó M, Zhang C, Allen JJ et al. Cyclindependent kinase control of theinitiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol 2012; 19: 1108-1115.
77. Baumli S, Hole AJ, Wang LZ, Noble ME, Endicott JA. The CDK9 tail determines the reaction pathway of positive transcription elongation factor b. Structure 2012; 20: 1788-1795.
78. Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD et al. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 2007; 6: 3114-3131.
79. Garrofé-Ochoa X, Cosialls AM, Ribas J, Gil J, Boix J. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds. Apoptosis 2011; 16: 660-670.
80. Lee JH, Min C, Kwak SJ, Yeon-Sun Seong YS. Genomewide transcription profiles altered by BMI-1026 and Roscovitine and its implication in cellular senescence. Biochip J 2012; 6: 362-371.
81. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
82. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970.
83. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2013; 32: 1059-1065.
84. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012; 21: 362-373.
85. Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V et al. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 2012; 31: 5193-5200.
86. Breuer D, Kotelkin A, Ammosova T, Kumari N, Ivanov A, Ilatovskiy AV et al. CDK2 regulates HIV-1transcription by phosphorylation of CDK9 on serine 90. Retrovirology 2012; 9: 94.
87. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S et al. The Aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 2011; 10: 2115-2123.
88. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
89. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674.
90. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1: 376-386.
91. Sharma K, Weber C, Baierlein M, Greff Z, Kéri G, Cox J et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat Methods 2009; 6: 741-744.
92. Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S et al. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 2011; 13: 1026-1034.